{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T01:59:25Z","timestamp":1781747965563,"version":"3.54.5"},"reference-count":29,"publisher":"Norwegian Medical Association","issue":"12\/13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2016,7,5]]},"DOI":"10.4045\/tidsskr.15.1259","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T06:29:36Z","timestamp":1467786576000},"page":"1089-94","source":"Crossref","is-referenced-by-count":4,"title":["Myasthenia gravis \u2013 diagnostikk og behandling"],"prefix":"10.4045","volume":"136","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Kerty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sissel","family":"L\u00f8seth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Mygland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Tallaksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"3500961_ref_1","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Myasthenia and the neuromuscular junction. Curr Opin Neurol 2012; 25: 523\u2009\u2013\u20099.","DOI":"10.1097\/WCO.0b013e3283572588"},{"key":"3500961_ref_2","doi-asserted-by":"crossref","unstructured":"Querol L, Illa I. Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 2013; 26: 459\u2009\u2013\u200965.","DOI":"10.1097\/WCO.0b013e328364c079"},{"key":"3500961_ref_3","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015; 14: 1023\u2009\u2013\u200936.","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"3500961_ref_4","doi-asserted-by":"crossref","unstructured":"Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36\u2009\u2013\u200940.","DOI":"10.1002\/mus.22006"},{"key":"3500961_ref_5","first-page":"150\u2009\u2013\u20091","volume":"73","author":"Heldal AT, Owe JF, Gilhus NE et al","year":"Neurology","journal-title":"5"},{"key":"3500961_ref_6","doi-asserted-by":"crossref","unstructured":"Andersen JB, Engeland A, Owe JF et al. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010; 17: 1445\u2009\u2013\u200950.","DOI":"10.1111\/j.1468-1331.2010.03089.x"},{"key":"3500961_ref_7","doi-asserted-by":"crossref","unstructured":"Carr AS, Cardwell CR, McCarron PO et al. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010; 10: 46.","DOI":"10.1186\/1471-2377-10-46"},{"key":"3500961_ref_8","doi-asserted-by":"crossref","unstructured":"Liew WKM, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr 2013; 25: 694\u2009\u2013\u2009700.","DOI":"10.1097\/MOP.0b013e328365ad16"},{"key":"3500961_ref_9","doi-asserted-by":"crossref","unstructured":"Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 2006; 77: 203\u2009\u2013\u20097.","DOI":"10.1136\/jnnp.2005.072355"},{"key":"3500961_ref_10","doi-asserted-by":"crossref","unstructured":"Kerty E, Elsais A, Argov Z et al. EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J\u00a0Neurol 2014; 21: 687\u2009\u2013\u200993.","DOI":"10.1111\/ene.12359"},{"key":"3500961_ref_11","doi-asserted-by":"crossref","unstructured":"Chiou-Tan FY, Gilchrist JM. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. Muscle Nerve 2015; 52: 455\u2009\u2013\u200962.","DOI":"10.1002\/mus.24745"},{"key":"3500961_ref_12","doi-asserted-by":"crossref","unstructured":"Romi F, Skeie GO, Gilhus NE et al. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005; 62: 442\u2009\u2013\u20096.","DOI":"10.1001\/archneur.62.3.442"},{"key":"3500961_ref_13","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Nacu A, Andersen JB et al. Myasthenia gravis and risks for comorbidity. Eur J Neurol 2015; 22: 17\u2009\u2013\u200923.","DOI":"10.1111\/ene.12599"},{"key":"3500961_ref_14","doi-asserted-by":"crossref","unstructured":"Heldal AT, Eide GE, Romi F et al. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS One 2014; 9: e114060.","DOI":"10.1371\/journal.pone.0114060"},{"key":"3500961_ref_15","doi-asserted-by":"crossref","unstructured":"Klein R, Marx A, Str\u00f6bel P et al. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 2013; 74: 1184\u2009\u2013\u200993.","DOI":"10.1016\/j.humimm.2013.06.020"},{"key":"3500961_ref_16","doi-asserted-by":"crossref","unstructured":"Maniaol AH, Elsais A, Lorentzen \u00c5R et al. Late onset myasthenia gravis is associated with HLA DRB1*15: 01 in the Norwegian population. PLoS One 2012; 7: e36603.","DOI":"10.1371\/journal.pone.0036603"},{"key":"3500961_ref_17","doi-asserted-by":"crossref","unstructured":"Zisimopoulou P, Brenner T, Trakas N et al. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013; 12: 924\u2009\u2013\u200930.","DOI":"10.1016\/j.autrev.2013.03.002"},{"key":"3500961_ref_18","doi-asserted-by":"crossref","unstructured":"Skeie GO, Apostolski S, Evoli A et al; European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893\u2009\u2013\u2009902.","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"key":"3500961_ref_19","doi-asserted-by":"crossref","unstructured":"Pedersen EG, Potteg\u00e5rd A, Hallas J et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013; 20: 942\u2009\u2013\u20098.","DOI":"10.1111\/ene.12108"},{"key":"3500961_ref_20","first-page":"400\u2009\u2013\u20096","volume":"71","author":"Sanders DB, Hart IK, Mantegazza R et al","year":"Neurology","journal-title":"20"},{"key":"3500961_ref_21","doi-asserted-by":"crossref","unstructured":"Keung B, Robeson KR, DiCapua DB et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 2013; 84: 1407\u2009\u2013\u20099.","DOI":"10.1136\/jnnp-2012-303664"},{"key":"3500961_ref_22","doi-asserted-by":"crossref","unstructured":"Iorio R, Damato V, Alboini PE et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262: 1115\u2009\u2013\u20099.","DOI":"10.1007\/s00415-014-7532-3"},{"key":"3500961_ref_23","doi-asserted-by":"crossref","unstructured":"Cea G, Benatar M, Verdugo RJ et al. Thymectomy for non-thymomatous myasthenia gravis. (review). Cochrane Database Syst Rev 2013; 10: CD008111.","DOI":"10.1002\/14651858.CD008111.pub2"},{"key":"3500961_ref_24","doi-asserted-by":"crossref","unstructured":"Marx A, Pfister F, Schalke B et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013; 12: 875\u2009\u2013\u200984.","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"3500961_ref_25","doi-asserted-by":"crossref","unstructured":"Ye B, Tantai JC, Li W et al. Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma. World J Surg Oncol 2013; 11: 157\u2009\u2013\u200962.","DOI":"10.1186\/1477-7819-11-157"},{"key":"3500961_ref_26","first-page":"2017\u2009\u2013\u200923","volume":"76","author":"Barth D, Nabavi Nouri M, Ng E et al","year":"Neurology","journal-title":"26"},{"key":"3500961_ref_27","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. (review). Cochrane Database Syst Rev 2012; 12: CD002277.","DOI":"10.1002\/14651858.CD002277.pub4"},{"key":"3500961_ref_28","doi-asserted-by":"crossref","unstructured":"Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007; 14: 38\u2009\u2013\u200943.","DOI":"10.1111\/j.1468-1331.2006.01538.x"},{"key":"3500961_ref_29","doi-asserted-by":"crossref","unstructured":"Norwood F, Dhanjal M, Hill M et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry 2014; 85: 538\u2009\u2013\u200943.","DOI":"10.1136\/jnnp-2013-305572"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:12:36Z","timestamp":1781669556000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2016\/07\/klinisk-oversikt\/myasthenia-gravis-diagnostikk-og-behandling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":29,"journal-issue":{"issue":"12\/13","published-print":{"date-parts":[[2016,7,5]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.15.1259","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]}}}